Biotricity INC 10-K annual reports

Biotricity Inc. announced its fiscal year 2026 results, showing revenue growth and a reduced net loss, while highlighting ongoing product development and market expansion.

Biotricity Inc. filed an amended annual report for fiscal year 2025, showcasing increased revenue and improved gross profit, while still facing significant accumulated deficits and a going concern qualification from its auditors following its delisting from Nasdaq.

Biotricity, a medical technology company, reported increased revenue and gross profit for fiscal year 2025, alongside a positive Adjusted EBITDA for the fourth quarter, despite continued net losses and an auditor's 'going concern' warning.

Biotricity Inc. has refiled its annual report on Form 10-K/A to include the consent of its independent registered public accounting firm, SRCO Professional Corporation.

Biotricity Inc.'s annual 10-K filing outlines the company's share structure, financial performance, and strategic direction in the medical technology sector.